TG Therapeutics Inc TGTX:NASDAQ
RT Quote | Last NYSE Arca, VOL From CTA | USD
After Hours: Last | 7:51 PM EDT39.86
-0.25 (-0.62%)
-0.25 (-0.62%)Volume
44,910
Close
40.11
+3.47 (+9.47%)
+3.47 (+9.47%)Volume
3,544,534
52 week range
25.28 - 44.65
- Open38.57
- Day High41.34
- Day Low37.96
- Prev Close36.64
- 52 Week High44.65
- 52 Week High Date05/08/26
- 52 Week Low25.28
- 52 Week Low Date08/11/25
Latest On TG Therapeutics Inc
Key Stats
- Market Cap6.14B
- Shares Out153.08M
- 10 Day Average Volume1.36M
- Dividend-
- Dividend Yield-
- Beta1.68
Latest On TG Therapeutics Inc
KEY STATS
- Open38.57
- Day High41.34
- Day Low37.96
- Prev Close36.64
- 52 Week High44.65
- 52 Week High Date05/08/26
- 52 Week Low25.28
- 52 Week Low Date08/11/25
- Market Cap6.14B
- Shares Out153.08M
- 10 Day Average Volume1.36M
- Dividend-
- Dividend Yield-
- Beta1.68
RATIOS/PROFITABILITY
- EPS (TTM)2.87
- P/E (TTM)13.98
- Fwd P/E (NTM)22.67
- EBITDA (TTM)149.58M
- ROE (TTM)112.60%
- Revenue (TTM)700.349M
- Gross Margin (TTM)83.05%
- Net Margin (TTM)65.95%
- Debt To Equity (MRQ)127.78%
EVENTS
- Earnings Date08/03/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
- TG Therapeutics rises 10.6%TipRanks
Related Video
watch now
Profile
MORETG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults...
Michael Weiss J.D.
Chairman of the Board, President, Chief Executive Officer
Sean Power
Chief Financial Officer, Treasurer, Corporate Secretary
Address
3020 Carrington Mill Blvd., Suite 475
Morrisville, NC
27560-5435
United States